Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed
countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent …

Characterised by intraocular inflammation, non‐infectious uveitis includes a large group of
autoimmune and autoinflammatory diseases that either involve the eye alone or have both …

Purpose To analyze the factors associated with response (control of ocular inflammation and
corticosteroid-sparing effect) to biologics (anti–tumor necrosis factor [TNF]-α agents and …

Purpose: To compare the efficacy and safety of infliximab and interferon in patients with
refractory Behçet uveitis. Methods: Medical records of 20 patients treated with infliximab …

Introduction Noninfectious uveitis represents one of the leading causes of blindness in
developed Countries, compromising patients' quality of life and social functioning. The main …

Purpose: Several concerns have arisen with biosimilars in terms of immunogenicity, safety
issues, loss of efficacy, and extrapolation to other indications. The study aim was to evaluate …

Purpose To examine a large cohort of patients treated with biologic agents for active
noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU) and to compare …

Introduction: Noninfectious uveitis (NIU) is one of the leading causes of blindness
worldwide. In adult patients, anterior NIU is usually managed with topical corticosteroids. In …

Purpose To evaluate the outcomes of uveitic macular edema at 6 and 12 months in patients
treated with methotrexate or mycophenolate mofetil. Design Subanalysis of a block …

The mainstay of treatment for noninfectious uveitis (NIU) is immunosuppressant therapy.
This may come in a localized form that is administered specifically to the eye or a systemic …